14 Protocol Alert

New clinical trials recently added to the National Cancer Institute’s database oncology-times.com • BRAIN/CNS TUMORS and in Treating ENDOMETRIAL CANCER Phase: Phase II, Phase I Light Sedation or Intubated Patients with Stage I-III Triple- Levonorgestrel-Releasing Type: Treatment General Anesthesia in Reducing Negative Breast Cancer Intrauterine System with or without Age: 18 and over Complications and Length of Phase: Phase II Everolimus in Treating Patients with Trial IDs: SGN35-016, Hospital Stay in Patients With Brain Type: Treatment Atypical Hyperplasia or Stage IA NCI-2013-00461, NCT01874054 Cancer Undergoing Craniotomy Age: 18 to 70 Grade 1 Endometrial Cancer Phase: Phase IV Trial IDs: 2014-BRST-TNBC-LQT, Phase: Phase II Safety, Tolerability, and Efficacy of October 10, 2015 Type: Supportive care, Treatment NCI-2015-01416, STUDY00002467, Type: Biomarker/Laboratory analysis, TAK-659 in Adults With Relapsed • Age: 19 and over NCT02413320 Treatment or Refractory Acute Myelogenous Trial IDs: OSU-12161, NCI-2014- Age: 18 and over Leukemia (AML) 01110, 2014C0007, NCT02193568 Trial IDs: 2014-0944, Phase: Phase II, Phase I CERVICAL CANCER NCI-2015-00919, NCT02397083 Type: Treatment Pazopanib Hydrochloride and Age: 18 and over BREAST CANCER Hydrochloride in Treating Trial IDs: C34002, NCI-2015-00064, Study to Evaluate the Efficacy and Patients with Stage IVB or Recurrent HEAD & NECK/ U1111-1163-2185, NCT02323113 Safety of Mesylate in Cervical Cancer ORAL CANCER Combination With Pembrolizumab Phase: Phase II Photodynamic Therapy With HPPH A Study of Duvelisib in Combination Oncology Times in Subjects With Metastatic Triple- Type: Biomarker/Laboratory analysis, in Treating Patients With Squamous With Rituximab or Obinutuzumab in Negative Breast Cancer (mTNBC) Treatment Cell Carcinoma of the Oral Cavity Subjects With Previously Untreated Phase: Phase II, Phase I Age: 18 and over Phase: Phase II CD20+ Follicular Lymphoma Type: Treatment Trial IDs: 2014-0625, Type: Biomarker/Laboratory analysis, (CONTEMPO) Age: 18 and over NCI-2015-00211, NCT02348398 Treatment Phase: Phase II, Phase I Trial IDs: E7389-M001-218, Age: 18 and over Type: Biomarker/Laboratory analysis, NCI-2015-01436, KEYNOTE-150, Trial IDs: I 246513, NCI-2014-00756, Treatment NCT02513472 COLORECTAL CANCER NCT02119728 Age: 18 and over A Study Comparing the Efficacy and Trial IDs: IPI-145-19, Hypofractionated Regional Nodal Safety of RO5520985 and FOLFOX Surgery with or without Stereotactic NCI-2015-01462, Radiation Therapy in Treating Older With Bevacizumab and FOLFOX in Body Radiotherapy in Treating Patients NCT02391545 Patients with Breast Cancer Who with Previously-Irradiated Have Undergone Surgery Head and Neck Cancer Ruxolitinib Phosphate or Dasatinib Phase: Phase II Phase: Phase II with Chemotherapy in Treating Type: Biomarker/Laboratory analysis, Type: Treatment Patients with Relapsed or Refractory Treatment Age: 18 and over Philadelphia Chromosome-Like Age: 50 and over Trial IDs: 14-151, NCI-2015- Acute Lymphoblastic Leukemia Trial IDs: MCC-15-10994, 01424, NCT02516969 Phase: Phase II, Phase I NCI-2015-01317, NCT02515110 Type: Treatment Safety And Efficacy Age: 10 and over Panitumumab, Albumin- Study Of Palbociclib Trial IDs: 2014-0521, Stabilized Nanoparticle Formulation, Plus Cetuximab Versus NCI-2015-00779, NCT02420717 and in Treating Cetuximab To Treat Head Patients with HER2-Negative And Neck Cancer Akt/ERK Inhibitor ONC201 in Primary Inflammatory Breast Phase: Phase II Treating Patients with Relapsed or Cancer Receiving Combination Type: Treatment Refractory Mantle Cell Lymphoma, Chemotherapy and Surgery Age: 18 and over Diffuse Large B-cell Lymphoma, or Phase: Phase II Trial IDs: A5481044, NCI- Transformed Large Cell Lymphoma Type: Biomarker/Laboratory analysis, 2015-01296, 2015-000515- Phase: Phase II, Phase I Treatment 41, NCT02499120 Type: Treatment Age: 18 and over Patients With Untreated Metastatic Age: 18 and over Trial IDs: 2008-0372, Colorectal Cancer (McCAVE) in Measuring Tumor Trial IDs: 2014-0630, NCI-2015- NCI-2012-00935, NCI-2010-02235, Phase: Phase II Response in Patients with HPV 00706, NCT02420795 NCT01036087 Type: Treatment Positive or Negative Head and Neck Age: 18 and over Squamous Cell Carcinoma That Can Tocladesine in Treating Patients with Metformin Hydrochloride in Trial IDs: BP29262, Be Removed by Surgery Relapsed or Refractory Acute Myeloid Reducing Treatment-Related NCI-2014-01282, Phase: Phase II Leukemia Neuropathy in Patients with Stage NCT02141295 Type: Treatment Phase: Phase II, Phase I I-IV Breast Cancer Undergoing Age: 18 and over Type: Biomarker/Laboratory analysis, Treatment with Paclitaxel Study of Pembrolizumab in Trial IDs: 1404013771, Treatment Phase: Phase II Combination With Chemotherapy NCI-2015-01437, 200 FR. 4 (2012-1), Age: 18 and over Type: Supportive care for Patients With Advanced NCT02178072 Trial IDs: 14269, NCI-2015-00871, Age: Over 18 Colorectal Cancer 116608, 120003, NCT02509546 Trial IDs: 2014-0438, Phase: Phase II NCI-2015-00510, NCT02360059 Type: Treatment LEUKEMIA/ An Efficacy and Safety Study of Age: 18 and over LYMPHOMA/MDS (DACOGEN) Plus JNJ- Carboplatin and or Trial IDs: HCRN GI14-186, Study of Brentuximab Vedotin 56022473 (Anti CD123) Versus Carboplatin and Paclitaxel Followed NCI-2015-01466, Combined With in Decitabine (DACOGEN) Alone in by Hydrochloride NCT02375672 Patients With Hodgkin Lymphoma Participants With Acute Myeloid 15

PROTOCOL ALERT Treating Patients with Advanced Trial IDs: HM-EMSI-202, NCI-2015- Cell Transplant in Treating Patients Oncology Times Continued from page 14 Refractory Solid Tumors or 01440, NCT02485652 With Multiple Myeloma Lymphomas Phase: Phase II Leukemia (AML) Ineligible for Phase: Phase II Type: Biomarker/Laboratory analysis, Intensive Chemotherapy Type: Biomarker/Laboratory analysis, MELANOMA Treatment Phase: Phase II Treatment Interleukin-12 Gene Electroporation Age: 18 to 72 Type: Treatment Age: 18 and over Therapy and Pembrolizumab in Trial IDs: 11-12-434, Age: 65 and over Trial IDs: EAY131, NCI-2015-00054, Treating Patients with Locally NCI-2013-01207, 11-102, Trial IDs: CR107273, NCI-2015-01326, EAY131-A, EAY131-B, EAY131-E, Advanced or Metastatic Melanoma NCT01605032

56022473AML2002, NCT02472145 EAY131-F, EAY131-G, EAY131-H, Phase: Phase II •

EAY131-Q, EAY131-R, EAY131-U, Type: Biomarker/Laboratory analysis, , October 10, 2015 Meloxicam and Filgrastim in EAY131-V, NCT02465060 Treatment Hydrochloride, , and Collecting Peripheral Blood Stem Age: 18 and over before Stem Cell Cells for Transplant in Patients With FLT PET/CT in Measuring Response Trial IDs: CC #15852, NCI-2015- Transplant in Treating Patients with Multiple Myeloma or Non-Hodgkin in Patients with Previously Untreated 01300, 133438, 15852, NCT02493361 Refractory or Relapsed Multiple Lymphoma Acute Myeloid Leukemia Myeloma Phase: Phase II Phase: Phase II Pembrolizumab, Standard Phase: Phase II Type: Treatment Type: Diagnostic, Treatment Chemotherapy, Tumor Infiltrating Type: Biomarker/Laboratory analysis,

Age: 18 to 75 Age: 18 and over Lymphocytes, and High- or Low-Dose Treatment • oncology-times.com Trial IDs: IUCRO-0419, NCI-2014- Trial IDs: EAI141, Aldesleukin in Treating Patients with Age: 18 to 65 00470, NCT02078102 NCI-2015-00328, Metastatic Melanoma Trial IDs: 2014-0516, NCI-2015- NCT02392429 Phase: Phase II 01308, NCT02506959 Augmented Berlin-Frankfurt- Type: Biomarker/Laboratory analysis, Munster Therapy and Ofatumumab Donor Hematopoietic Stem Cell Treatment Sotatercept in Increasing Bone in Treating Patients with B-cell Transplant and Combination Age: 18 and over Mineral Density in Patients with Acute Lymphoblastic Leukemia or Chemotherapy as Initial Salvage Trial IDs: 2014-0922, NCI-2015- Multiple Myeloma with Complete Lymphoblastic Lymphoma Therapy in Treating Patients with 01395, NCT02500576 or Very Good Partial Response after Phase: Phase II Acute Myeloid Leukemia Refractory Previous Treatment Type: Treatment to High-Dose -Based Phase: Phase II Age: 12 to 30 Induction Chemotherapy MYELOMA Type: Biomarker/Laboratory analysis, Trial IDs: 2014-0396, NCI-2015- Phase: Phase II Busulfan, Melphalan, and Supportive care 00967, NCI-2010-01164, NCI-2012- Type: Treatment Before First-Line Stem Age: Over 18 01650, NCT02419469 Age: 18 to 60 continued on page 16 Trial IDs: 2014-0358, NCI-2015- Bendamustine Hydrochloride, 00849, NCT02441803 Obinutuzumab, and Dexamethasone in Treating Older Patients with Study of Efficacy and Safety of Diffuse Large B-cell Lymphoma CTL019 in Adult DLBCL Patients Phase: Phase II Phase: Phase II To Reach OT: Type: Biomarker/Laboratory analysis, Type: Treatment Treatment Age: 18 and over n Editorial, ­Permissions, or n Classified Advertising: Age: 70 and over Trial IDs: CCTL019C2201, NCI- Publishing Matters: Joe Anzuena National Account Trial IDs: IRB14-1120, NCI-2015- 2015-01461, 2014-003060-20, Oncology Times Manager Wolters Kluwer Health 00355, NCT02420210 NCT02445248 333 Seventh Ave. 19th Fl. Two Commerce Square New York, NY 10001 2001 Market Street Philadelphia, Pembrolizumab in Treating Patients [email protected] PA 19103 215 521-8532 with Relapsed or Refractory Chronic LUNG CANCER fax 215 701-2410 Lymphocytic Leukemia or Other Erlotinib Hydrochloride and Hsp90 n Joe.Anzuena@­wolterskluwer.com Low-Grade B-Cell Non-Hodgkin Inhibitor AT13387 in Treating Advertising Sales: Lymphomas Patients with Recurrent or Metastatic Brian Parker n Phase: Phase II Non-small Cell Lung Cancer Wolters Kluwer Health Circulation Matters: Type: Treatment Phase: Phase II, Phase I Learning, Research & Practice Physicians, nurses, and Age: 18 and over Type: Biomarker/Laboratory analysis, Two Commerce Square, pharmacists ­specializing Trial IDs: MC1485, NCI-2014-02561, Treatment 2001 Market St., in oncology and related Mod14-005666-04, NCT02332980 Age: 18 and over Philadelphia, ­specialties within the U.S. are Trial IDs: PHI-80, eligible for a free subscription. PA 19103; Study of High-Dose Rituximab With NCI-2015-01411, 9878, To place a new order or 215-521-8969, as Treatment for NCT02535338 renew or cancel an existing Primary Central Nervous System fax: 410-558-6851; subscription, go to (CNS) Lymphoma Selinexor and Docetaxel in Treating [email protected] www.lwwforms.com/OT Phase: Phase II Patients with Recurrent or Metastatic Type: Treatment Squamous Cell Lung Cancer n Custom Publishing: To change your address, Age: 18 and over Phase: Phase II, Phase I Ben Harkinson Trial IDs: SCRI CNS 20, Type: Biomarker/Laboratory analysis, call 800-430-5450 or Wolters Kluwer Health Learning, NCI-2015-01353, NCT02113007 Treatment email [email protected] Research & Practice Age: 18 and over (for quickest ­service, Rituximab and Pembrolizumab Trial IDs: OSU-14152, NCI-2015- 100 River Ridge Dr., include account number, in Treating Patients with Relapsed 01165, NCT02536495 Suite 207, located above your Follicular Lymphoma Norwood, name on the mailing Phase: Phase II Study Evaluating the Efficacy, Safety MA 02062; label). Type: Treatment and in Patient 781-440-4854, Age: 18 and over With T790M-positive Non-small Cell mobile: 646-574-0286, n Reprints: Bridget Quinn Trial IDs: 2014-0539, NCI-2015- Lung Cancer fax: 646-607-4253; 215-521-8807; fax: 215-405-3812 01307, Merck protocol - 3475-110, Phase: Phase II NCT02446457 Type: Biomarker/Laboratory analysis, benjamin.harkinson@­ bridget.quinn@wolterskluwer. NCI-MATCH: Targeted Therapy Treatment wolterskluwer.com com Directed by Genetic Testing in Age: 20 and over 16 PROTOCOL ALERT Trial IDs: 201503074, MISCELLANEOUS/ Trial IDs: 15-005, NCI-2015-00917, Continued from page 15 NCI-2015-00425, MULTIPLE/OTHER NCT02425904 NCT02352831 Brody Belt in Improving Quality Trial IDs: IUCRO-0428, NCI-2014- of Life in Patients Using Urinary Cognitive-Behavioral Weight Loss 01967, 1408844060, ACE-011- Efficacy and Safety Study of Drainage Bags Program in Reducing Weight in MM-PI-0008, NCT02230917 PBI-05204 in Patients With Phase: No phase specified Obese Women Stage IV Metastatic Pancreatic Type: Supportive care Phase: Phase III Adenocarcinoma Age: 18 and over Type: Behavioral study, Biomarker/ OVARIAN CANCER Phase: Phase II Trial IDs: I 153209, NCI-2010-00339, Laboratory analysis

oncology-times.com Chemoimmunotherapy and Vaccine Type: Treatment NCT01228864 Age: 21 and over • Therapy in Treating Patients with Age: 18 and over Trial IDs: UCSD 20133218, NCI-2013- Recurrent Ovarian Cancer Trial IDs: 2014-4350, CD34-Positive Donor Stem Cell 01966, 110876, NCT01424007 Phase: Phase II, Phase I NCI-2015-01388, NCT02329717 Boost in Improving Graft Function in Type: Treatment Patients Who Have Undergone Stem Collection and Storage of Tissue and Age: 18 and over Combination Chemotherapy in Cell Transplant Blood Samples from Patients with Trial IDs: UPCI 11-128, NCI-2015- Treating Patients with Pancreatic Phase: No phase specified Cancer 00800, 11-128, NCT02432378 Cancer before Undergoing Surgery Type: Treatment Phase: No phase specified Phase: Phase II Age: Not specified Type: Tissue collection/Repository October 10, 2015 Dose Dense Paclitaxel with Type: Biomarker/Laboratory analysis, Trial IDs: 2015-0295, Age: 19 and over • Pembrolizumab in Platinum Treatment NCI-2015-00979, NCT02438904 Trial IDs: 9846, NCI-2015-00863, Resistant Ovarian Cancer Age: 18 to 75 P9846, P9846_R02PAPPHOLD01, Phase: Phase II Trial IDs: CASE4214, Chaplain-Led Counseling in NCT02474160 Type: Treatment NCI-2014-02277, NCT02345460 Improving Quality of Life in Age: 18 and over Caregivers of Patients With Life- Combination Chemotherapy and Trial IDs: MCC-18207, Regorafenib and Gemcitabine Limiting Illness Stem Cell Transplant in Treating NCI-2015-01418, NCT02440425 Hydrochloride as Second-Line Phase: No phase specified Patients With Recurrent or Therapy in Treating Patients with Type: Supportive care Progressive Germ Cell Tumors MEDI4736 and or Metastatic Pancreatic Cancer Age: 18 and over Phase: Phase II Oncology Times Cediranib Maleate in Treating Phase: Phase II Trial IDs: Pro00039370, Type: Biomarker/Laboratory analysis, Patients with Advanced Solid Tumors Type: Treatment NCI-2014-00029, Treatment or Recurrent Ovarian, Fallopian Age: 18 and over NCT01768221 Age: Not specified Tube, or Primary Peritoneal Cancer Trial IDs: CASE5214, Trial IDs: CCI-09-00196, NCI-2013- Phase: Phase II, Phase I NCI-2015-00146, Cidofovir or Best Supportive Care 01195, NCT01270742 Type: Biomarker/Laboratory analysis, NCT02383433 in Treating BK Virus-Related Treatment Hemorrhagic Cystitis in Patients Convection-Enhanced Delivery of Age: 18 and over Previously Treated with Stem Cell Anti-EGFRvIII Immunotoxin MR1-1 Trial IDs: 15-C-0145, NCI- PROSTATE CANCER Transplant in Treating Patients With Residual, 2015-01401, 344406, P141726, Effects of Endocrine Therapy with or Phase: Phase II Progressive, or Recurrent Gliomas or NCT02484404 without Trametinib or Dasatinib in Type: Treatment Brain Metastases Patients with Localized, Untreated Age: 6 and over Phase: Phase I Prostate Cancer Undergoing Surgery Trial IDs: 2010-0518, Type: Treatment PANCREATIC CANCER Phase: Phase II NCI-2011-00250, NCT01295645 Age: 18 and over Tosedostat and in Type: Biomarker/Laboratory analysis, Trial IDs: 00011617, NCI-2011-03834, Treating Patients with Pancreatic Treatment in Treating Patients with NCT01009866 Cancer That is Advanced, Metastatic, Age: 18 and over Recurrent or Refractory Langerhans or Cannot Be Removed by Surgery Trial IDs: IRB#13-000714, Cell Histiocytosis Copper Cu 64 Anti-CEA Monoclonal Phase: Phase II, Phase I NCI-2015-01448, EMT13001, Phase: Phase II Antibody M5A PET in Diagnosing Type: Treatment NCI-2014-02414, Type: Treatment Patients with CEA Positive Cancer Age: 18 and over NCT01990196 Age: Not specified Phase: No phase specified

OT on Your iPad—

Easier Reading, Bonus Features!

bit.ly/OT-iPadApp 17

PROTOCOL ALERT Age: 18 and over Type: Biomarker/Laboratory analysis, Age: 2 and over Oncology Times Continued from page 16 Trial IDs: Pro00013947, NCI-2013- Treatment Trial IDs: LA38-0411, 00579, NCT01274377 Age: Not specified NCI-2014-01229, Type: Biomarker/Laboratory analysis, . Trial IDs: 00015791, NCT02041299 Diagnostic Donor Cytomegalovirus-Specific NCI-2011-03853, Age: 18 and over Cytotoxic T-Lymphocytes in NCT01372228 Efficacy and Safety Study of CSJ148 in Trial IDs: 14238, NCI-2014-02079, Treating Patients with a Persistent Stem Cell Transplant Patients 116082, 14206, 14238/117640, Cytomegalovirus Infection after Stem Donor Peripheral Blood Stem Cell Phase: Phase II, Phase I NCT02293954 Cell Transplant Transplant in Treating Patients With Type: Biomarker/Laboratory analysis,

Phase: Phase II Severe Autoimmune Diseases Prevention •

Cytoreductive Surgery and Type: Treatment Phase: No phase specified Age: 18 and over October 10, 2015 Hyperthermic Intraperitoneal Age: Not specified Type: Treatment Trial IDs: CCSJ148X2201, Followed by Standard Trial IDs: 2013-0657, NCI-2014-01990, Age: 18 to 69 NCI-2015-00634, NCT02268526 Chemotherapy in Treating Patients NCT02210078 Trial IDs: Pro00010324, With Peritoneal Carcinomatosis NCI-2013-01245, NCT00849745 Efficacy Study of Tempol to Prevent Phase: Phase II Donor Cytotoxic T Lymphocytes in Hair Loss From Radiotherapy to the Type: Biomarker/Laboratory analysis, Treating Cytomegalovirus Infection Donor Regulatory T Lymphocytes Brain Treatment in Patients Who Have Undergone in Preventing Acute Graft-Versus- Phase: Phase II

Age: 18 and over Donor Stem Cell Transplant Host Disease in Patients Undergoing Type: Prevention • oncology-times.com Trial IDs: 11-09-332, NCI-2013-01214, Phase: Phase II Donor Stem Cell Transplant Age: 18 and over 11-075, NCT02040142 Type: Biomarker/Laboratory analysis, Phase: Phase I Trial IDs: MITO 02-03, Supportive care Type: Biomarker/Laboratory analysis, NCI-2012-00422, NCT00801086 Dendritic Cell Vaccine, Recombinant Age: Not specified Prevention, Treatment Interferon Alfa, Rintatolimod, and Trial IDs: 12-086, NCI-2012-01238, Age: 18 to 70 Eligibility Screening and Research After Surgery in Treating NCT01646645 Trial IDs: 17263, NCI-2014-01426, Sample Collection in Determining Patients with Peritoneal Surface MCC-17263, NCT01795573 Patient Eligibility to Participate in Cancers Donor Multi-virus-Specific Cytotoxic Clinical Trials Phase: Phase II T Lymphocytes in Treating Epstein- Donor Stem Cell Transplant after Phase: No phase specified Type: Treatment Barr Virus, Cytomegalovirus, Busulfan and Phosphate Type: Biomarker/Laboratory analysis, Age: 18 and over Adenovirus, Human Herpes Virus 6, with or without Anti-thymocyte Health services research Trial IDs: UPCI 12-110, NCI-2014- and BK Virus Infections in Patients Globulin in Treating Patients with Age: Not specified 01357, 02151448, NCT02151448 Who Have Undergone Donor Stem Inherited Metabolic Disorders, Severe Trial IDs: 01-C-0129, Cell Transplant Osteopetrosis, or Rett Syndrome NCI-2013-02022, 010129, 01-C-0129 Dexmedetomidine Hydrochloride Phase: Phase II, Phase I Phase: Phase II M, NCT00026754 in Reducing Pain in Patients Type: Biomarker/Laboratory analysis, Type: Biomarker/Laboratory analysis, Undergoing Thoracic Surgery Supportive care Treatment A Study of Doxorubicin Plus Phase: Phase III Age: Not specified Age: 55 and under Olaratumab (LY3012207) in Type: Supportive care Trial IDs: H-29966, NCI-2012- Trial IDs: 2013LS104, Participants With Advanced or Age: 21 and over 02979, ARMS, H-29966 ARMS, NCI-2014-02309, 1406M51542, Metastatic Soft Tissue Sarcoma Trial IDs: 13-163, NCI-2013-02150, NCT01570283 MT2013-31, NCT02171104 Phase: Phase III NCT01973452 Type: Biomarker/Laboratory analysis, Donor Multivirus-Specific T-Cells Effect of Radiation on Bone in Treatment Eltrombopag Olamine in Increasing in Treating Patients with Persistent Patients with Cancer of the Sacrum Age: 18 and over Platelet Counts in Patients or Recurrent Viral Infections after Phase: No phase specified Trial IDs: 15677, Undergoing Transplant Donor Stem Cell Transplant Type: Biomarker/Laboratory analysis, NCI-2015-01298, 2015-000134-30, Phase: Phase II Phase: No phase specified Supportive care, Treatment I5B-MC-JGDJ, NCT02451943 Type: Biomarker/Laboratory analysis, Type: Biomarker/Laboratory analysis, Age: 18 and over Supportive care Treatment Trial IDs: 14-208, Acupuncture in Treating Age: 18 and over Age: Not specified NCI-2015-00893, Chemotherapy-Induced Neuropathy Trial IDs: 2012-0920, NCI-2013- Trial IDs: H-33903, NCI-2014-00896, NCT02323295 in Cancer Survivors 02348, NCT01927731 CHARMS, NCT02108522 Phase: Phase II, Phase I Efficacy and Safety of Ferriprox® in Type: Supportive care Endoscopic Dilation With or Without Donor Peripheral Blood Stem Cell Patients With Sickle Cell Disease or Age: 18 and over Triamcinolone in Treating Patients Transplant in Treating Patients With Other Anemias Trial IDs: 2013-0930, With Anastomotic or Radiation Inherited Metabolic Disorders Phase: Phase IV NCI-2014-01466, Induced Difficulty Swallowing Phase: Phase II, Phase I Type: Treatment NCT02168894 Phase: No phase specified Type: Supportive care Age: 18 and over Trial IDs: MCC 17316, NCI-2013- 01370, 13.05.0023, NCT01873573

Endoscopic Radiofrequency Ablation in Treating Patients With Malignant Biliary Obstruction Phase: No phase specified Type: Supportive care, Treatment Age: 18 and over Sign up for our free e-newsletter and receive notification Trial IDs: 11-405, NCI-2012-00258, NCT01543607 when each issue becomes available and when other new Donor Cytomegalovirus-Specific Cytotoxic T Lymphocytes in Treating Patients Undergoing Donor Stem Cell content is posted online: Transplant Phase: No phase specified bit.ly/OT-alerts Type: Biomarker/Laboratory analysis, Treatment